|
1
|
Karnib HH, Gharavi AG, Aftimos G, Mahfoud
Z, Saad R, Gemayel E, Masri B, Assaad S, Badr KF and Ziyadeh FN: A
5-year survey of biopsy proven kidney diseases in Lebanon:
Significant variation in prevalence of primary glomerular diseases
by age, population structure and consanguinity. Nephrol Dial
Transplant. 25:3962–3969. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goto M, Wakai K, Kawamura T, Ando M, Endoh
M and Tomino Y: A scoring system to predict renal outcome in IgA
nephropathy: A nationwide 10-year prospective cohort study. Nephrol
Dial Transplant. 24:3068–3074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kiryluk K, Li Y, Sanna-Cherchi S,
Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P,
Scolari F, et al: Geographic differences in genetic susceptibility
to IgA nephropathy: GWAS replication study and geospatial risk
analysis. PLoS Genet. 8:e10027652012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chacko B: IgA nephropathy in India: What
we do know. Ren Fail. 33:102–107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto R, Nagasawa Y, Shoji T, Inoue K,
Uehata T, Kaneko T, Okada T, Yamauchi A, Tsubakihara Y, Imai E, et
al: A candidate gene approach to genetic prognostic factors of IgA
nephropathy-a result of polymorphism research to distinguish
genetic factors contributing to progression of IgA nephropathy
(PREDICT-IgAN). Nephrol Dial Transplant. 24:3686–3694. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaartinen K, Syrjänen J, Porsti I,
Harmoinen A, Pasternack A, Huhtala H, Niemelä O and Mustonen J:
Insulin resistance and the progression of IgA glomerulonephritis.
Nephrol Dial Transplant. 22:778–783. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonnet F, Deprele C, Sassolas A, Moulin P,
Alamartine E, Berthezène F and Berthoux F: Excessive body weight as
a new independent risk factor for clinical and pathological
progression in primary IgA nephritis. Am J Kidney Dis. 37:720–727.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen W, Liu Q, Liao Y, Yang Z, Chen J, Fu
J, Zhang J, Kong Y, Fu P, Lou T, et al: Outcomes of tacrolimus
therapy in adults with refractory membranous nephrotic syndrome: A
prospective, multicenter clinical trial. Am J Med Sci. 345:81–87.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loeffler K, Gowrishankar M and Yiu V:
Tacrolimus therapy in pediatric patients with treatment-resistant
nephrotic syndrome. Pediatr Nephrol. 19:281–287. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Girman P, Lipar K, Koznarova R, Boucek P,
Kriz J, Kocik M, Havrdova T, Adamec M and Saudek F: Similar early
complication rate in simultaneous pancreas and kidney recipients on
tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus
immunosuppressive regimens. Transplant Proc. 42:1999–2002. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Naesens M, Kuypers DR and Sarwal M:
Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol.
4:481–508. 2009.PubMed/NCBI
|
|
12
|
Flechner SM, Kobashigawa J and Klintmalm
G: Calcineurin inhibitor-sparing regimens in solid organ
transplantation: Focus on improving renal function and
nephrotoxicity. Clin Transplant. 22:1–15. 2008.PubMed/NCBI
|
|
13
|
Wierzbicka A, Pawłowska J, Socha P,
Jankowska I, Skorupa E, Teisseyre M, Ismail H, Czubkowski P and
Socha J: Lipid, carbohydrate metabolism and antioxidant status in
children after liver transplantation. Transplant Proc.
39:1523–1525. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noto T, Furuichi Y, Ishiye M, Matsuoka N,
Aramori I, Mutoh S and Yanagihara T: Tacrolimus (FK506) limits
accumulation of granulocytes and platelets and protects against
brain damage after transient focal cerebral ischemia in rat. Biol
Pharm Bull. 30:313–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aomatsu T, Imaeda H, Takahashi K, Fujimoto
T, Kasumi E, Yoden A, Tamai H, Fujiyama Y and Andoh A: Tacrolimus
(FK506) suppresses TNF-α-induced CCL2 (MCP-1) and CXCL10 (IP-10)
expression via the inhibition of p38 MAP kinase activation in human
colonic myofibroblasts. Int J Mol Med. 30:1152–1158.
2012.PubMed/NCBI
|
|
16
|
Faul C, Donnelly M, Merscher-Gomez S,
Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim
K, et al: The actin cytoskeleton of kidney podocytes is a direct
target of the antiproteinuric effect of cyclosporine A. Nat Med.
14:931–938. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mathieson PW: Proteinuria and immunity-an
overstated relationship? N Engl J Med. 359:2492–2494. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rostaing L, Cantarovich D, Mourad G, Budde
K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel
P, et al: Corticosteroid-free immunosuppression with tacrolimus,
mycophenolate mofetil and daclizumab induction in renal
transplantation. Transplantation. 79:807–814. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ,
Chen YQ, Zhang H and Wang HY: Tacrolimus improves the proteinuria
remission in patients with refractory IgA nephropathy. Am J
Nephrol. 35:312–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bayrak O, Seckiner I, Erturhan SM, Mizrak
S and Erbagci A: Analysis of changes in the glomerular filtration
rate as measured by the Cockroft-Gault formula in the early period
after percutaneous nephrolithotomy. Korean J Urol. 53:552–555.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee HS, Lee MS, Lee SM, Lee SY, Lee ES,
Lee EY, Park SY, Han JS, Kim S and Lee JS: Histological grading of
IgA nephropathy predicting renal outcome: Revisiting H. S. Lee's
glomerular grading system. Nephrol Dial Transplant. 20:342–348.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SM, Rao VM, Franklin WA, Schiffer MS,
Aronson AJ, Spargo BH and Katz AI: IgA nephropathy: Morphologic
predictors of progressive renal disease. Hum Pathol. 13:314–322.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y,
Xu JS, Huang SM, Wang LN, Huang W, et al: Modified glomerular
filtration rate estimating equation for Chinese patients with
chronic kidney disease. J Am Soc Nephrol. 17:2937–2944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferraro PM, Ferraccioli GF, Gambaro G,
Fulignati P and Costanzi S: Combined treatment with
renin-angiotensin system blockers and polyunsaturated fatty acids
in proteinuric IgA nephropathy: A randomized controlled trial.
Nephrol Dial Transplant. 24:156–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reich HN, Troyanov S, Scholey JW and
Cattran DC: Toronto Glomerulonephritis Registry: Remission of
proteinuria improves prognosis in IgA nephropathy. J Am Soc
Nephrol. 18:3177–3183. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manno C, Torres DD, Rossini M, Pesce F and
Schena FP: Randomized controlled clinical trial of corticosteroids
plus ACE-inhibitors with long-term follow-up in proteinuric IgA
nephropathy. Nephrol Dial Transplant. 24:3694–3701. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv J, Zhang H, Chen Y, Li G, Jiang L,
Singh AK and Wang H: Combination therapy of prednisone and ACE
inhibitor versus ACE-inhibitor therapy alone in patients with IgA
nephropathy: A randomized controlled trial. Am J Kidney Dis.
53:26–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aliabadi AZ, Pohanka E, Seebacher G,
Dunkler D, Kammerstätter D, Wolner E, Grimm M and Zuckermann AO:
Development of proteinuria after switch to sirolimus-based
immunosuppression in long-term cardiac transplant patients. Am J
Transplant. 8:854–861. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Skytte DM, Jaroszewski JW, Johansen KT,
Hansen SH, Hansen L, Nielsen PG and Frydenvang K: Some
transformations of tacrolimus, an immunosuppressive drug. Eur J
Pharm Sci. 48:514–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Westhoff TH and van der Giet M: Tacrolimus
in the treatment of idiopathic nephrotic syndrome. Expert Opin
Investig Drugs. 16:1099–1110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF,
Li XW, Chen JH and Wang HY: Chinese Nephropathy Membranous Study
Group: Tacrolimus combined with corticosteroids in treatment of
nephrotic idiopathic membranous nephropathy: A multicenter
randomized controlled trial. Am J Med Sci. 339:233–238. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roberti I and Vyas S: Long-term outcome of
children with steroid-resistant nephrotic syndrome treated with
tacrolimus. Pediatr Nephrol. 25:1117–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Li H, Ye H, Li Q, He X, Zhang X,
Chen Y, Han F, He Q, Wang H and Chen J: Tacrolimus therapy in
adults with steroid- and cyclophosphamide-resistant nephrotic
syndrome and normal or mildly reduced GFR. Am J Kidney Dis.
54:51–58. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
van Hooff JP, Christiaans MH and van
Duijnhoven EM: Tacrolimus and posttransplant diabetes mellitus in
renal transplantation. Transplantation. 79:1465–1469. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dittrich K, Knerr I, Rascher W and Dötsch
J: Transient insulin-dependent diabetes mellitus in children with
steroid-dependent idiopathic nephrotic syndrome during tacrolimus
treatment. Pediatr Nephrol. 21:958–961. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarkar S, Mondal R, Nandi M and Das AK:
Tacrolimus induced diabetic ketoacidosis in nephrotic syndrome.
Indian J Pediatr. 80:596–597. 2013. View Article : Google Scholar : PubMed/NCBI
|
